IperionX Limited(IPX)Earnings, Financials & Key Ratios

IPX•NASDAQ

$25.85

Price updated Jul 7, 2026

SectorBasic Materials IndustryIndustrial Materials Sub-IndustrySpecialty and Advanced Materials

AboutIperionX Limited engages in the exploration and development of mineral properties. It explores for epithermal and replacement style precious and base metal mineralization, as well as titanium, rare earth elements, silica sand, and zircon minerals. The company holds a 100% interest in the Milford project that includes 101 claims located in Utah, the United States. It also holds a 100% interest in Titan project covering an area of approximately 6,000 acres situated in Tennessee, the United States. The company was formerly known as Hyperion Metals Limited and changed its name to IperionX Limited in February 2022. IperionX Limited was incorporated in 2017 and is headquartered in Charlotte, North Carolina.Show more

Revenue$0
EBITDA-$38M-69.2%
Net Income-$35M-59.0%
EPS (Diluted)-1.20-20.0%
ROE-49.17%+20.5%

IPX Price & Volume

IperionX Limited (IPX) stock price & volume — 10-year historical chart

Loading chart...

Aggressive Capital Scaling Outpaces Commercial Revenue Realization

Investment Thesis • Updated 2026Q2

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Commercialization and liquidity risk

Key Thesis Takeaways

IperionX is currently in a high-risk, pre-revenue development phase, aggressively deploying capital to scale its proprietary HAMR technology at the Virginia Titanium Demonstration Facility.
While the company has successfully expanded its asset base to $129.2 million as of 2026Q2, the lack of recurring revenue and a persistent operating loss of $36.7 million create significant uncertainty regarding long-term commercial viability.
Investors should monitor the company's ability to transition from an R&D-heavy model to a revenue-generating industrial operation before the current $65.8 million cash buffer is exhausted.

Verdict Logic

the company's lack of revenue generation combined with a $36.7 million quarterly operating loss suggests that the current $65.8 million cash position may necessitate further dilutive financing to sustain operations.

IPX Growth Metrics

IperionX Limited (IPX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-360756.73%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-

Return on Capital

10 Years-143.1%

5 Years-213.2%

3 Years-78.55%

Last Year-52.72%

IPX Recent Earnings

IperionX Limited (IPX) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 6/12 qtrs (60%)

Q2 2026Latest

Mar 12, 2026

Metric

Actual

Est

EPS

$0.10-150.0%

$0.04

Rev

—

$4M

Q4 2025

Oct 3, 2025

Metric

Actual

Est

EPS

$1.20-2298.9%

$0.05

Rev

—

$1M

Q4 2025

Sep 30, 2025

Metric

Actual

Est

EPS

$1.20-2298.9%

$0.05

Rev

—

$1M

Q2 2025

Mar 13, 2025

Metric

Actual

Est

EPS

$0.06+29.4%

$0.09

Rev

—

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Mar 12, 2026	$0.10vs $0.04-150.0%	—vs $4M
Q4 2025	Oct 3, 2025	$1.20vs $0.05-2298.9%	—vs $1M
Q4 2025	Sep 30, 2025	$1.20vs $0.05-2298.9%	—vs $1M
Q2 2025	Mar 13, 2025	$0.06vs $0.09+29.4%	—

Based on last 12 quarters of dataView full earnings history →

Latest IPX News

Recent stock market news and headlines for IperionX Limited (IPX)

GlobeNewsWire·Jun 29, 2026

Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations

MILAN and BRIDGEWATER, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Zambon and Amneal Pharmaceuticals today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson's disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens.

Peers Comparison

Key metrics vs top competitors for IperionX Limited (IPX)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
IPXIperionX LimitedCurrent	$25.85	$869.39M	-21.54	—	—	-49.17%	—
TPVGTriplePoint Venture Growth BDC Corp.	$4.75	$192.85M	3.89	36.55%	-19.55%	-3.39%	—
ATLXAtlas Lithium Corporation	$3.37	$68.22M	-2.19	-86.14%	-23042.05%	-78.17%	—
AMTXAemetis, Inc.	$1.77	$120.62M	-1.38	-22.29%	-35.43%	—	—
ATIATI Inc.	$183.26	$25.09B	64.30	5.16%	9.26%	22.73%	—
CRSCarpenter Technology Corporation	$590.35	$29.33B	79.56	4.25%	15.82%	24.41%	—

Compare IPX vs Peers

IperionX Limited (IPX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs TPVG

Most directly comparable listed peer for IPX.

Scale Benchmark

vs GE

Larger-name benchmark to compare IPX against a more recognizable public peer.

Peer Set

Compare Top 5

vs TPVG, ATLX, AMTX, ATI

Get notified when IPX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

IPX Frequently Asked Questions

IperionX Limited (IPX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Is IPX profitable?

IperionX Limited (IPX) reported a net loss of $70.2M for fiscal year 2025.

Dividend & Returns

What is IPX's return on equity?

IperionX Limited (IPX) has a return on equity (ROE) of -49.2%. Negative ROE indicates the company is unprofitable.

What is IperionX Limited's free cash flow?

IperionX Limited (IPX) had negative free cash flow of $54.7M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in IPX back in 2017?

Total return calculator · dividends reinvested · 9+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

Mar 12, 2026

$0.10vs $0.04-150.0%

—vs $4M

Q4 2025

Oct 3, 2025

$1.20vs $0.05-2298.9%

—vs $1M

Q4 2025

Sep 30, 2025

$1.20vs $0.05-2298.9%

—vs $1M

Q2 2025

Mar 13, 2025

$0.06vs $0.09+29.4%

—

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

IPXIperionX LimitedCurrent

$25.85

$869.39M

-21.54

—

-49.17%

—

TPVGTriplePoint Venture Growth BDC Corp.

$4.75

$192.85M

3.89

36.55%

-19.55%

-3.39%

—

ATLXAtlas Lithium Corporation

$3.37

$68.22M

-2.19

-86.14%

-23042.05%

-78.17%

—

AMTXAemetis, Inc.

$1.77

$120.62M

-1.38

-22.29%

-35.43%

—

ATIATI Inc.

$183.26

$25.09B

64.30

5.16%

9.26%

22.73%

—

CRSCarpenter Technology Corporation

$590.35

$29.33B

79.56

4.25%

15.82%

24.41%

—